In a recent SGLT2 inhibitor era trial with 85 participants [10] and in a multinational trial including 263,525 patients [11], rehospitalisation rates due to heart failure were 32.2% or 19 per 100 patient-years in the Empagliflozin group and (30.8%) or eight per 100 patient-years [10] and 13.6 events per 100 patient-years [11]. This evidence concerns the gene SLC5A2 and heart failure.